EP0097196A1 - Procede d'isolation de chlamydia - Google Patents

Procede d'isolation de chlamydia

Info

Publication number
EP0097196A1
EP0097196A1 EP19830900038 EP83900038A EP0097196A1 EP 0097196 A1 EP0097196 A1 EP 0097196A1 EP 19830900038 EP19830900038 EP 19830900038 EP 83900038 A EP83900038 A EP 83900038A EP 0097196 A1 EP0097196 A1 EP 0097196A1
Authority
EP
European Patent Office
Prior art keywords
cells
chlamydia
cell
isolation
mccoy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP19830900038
Other languages
German (de)
English (en)
Inventor
Jorma Keski-Oja
Paul Partanen
Osmo Suovaniemi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Thermo Fisher Scientific Oy
Original Assignee
Labsystems Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Labsystems Oy filed Critical Labsystems Oy
Publication of EP0097196A1 publication Critical patent/EP0097196A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/24—Methods of sampling, or inoculating or spreading a sample; Methods of physically isolating an intact microorganisms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/04—Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/295—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Chlamydiales (o)

Definitions

  • the present invention is concerned with a method for the isolation of chlamydia for diagnosis of chlamydial infection, in which method a clinical sample is inoculated in the cells of a culture cell line, incubated, and the inclusions formed are detected most appropriately photo icroscopically after colouring.
  • Chlamydia trachomatis is a prokaryote orga- nism which infects eukaryote cells as an obligatory cell-internal parasite. Chlamydia trachomatis causes several diseases in man, and awareness of its signifi ⁇ cance for the public health is rapidly increasing (Paavonen, J.,1979, "Chlamydial infections. Micro- biological, diagnostic and clinical aspects", Med.Biol. 54:135-151; Paavonen, J., P.
  • the McCoy cell line originally used is closely related to the fibroblastic cancer cell line L929 of mice (Blyth, W.A., and J. Taverene, 1972, "Cultivation of TRIC agents: a comparison between the use of BHK-21 and irradiated McCoy cells", J.Hyg. 72: 121-128) .
  • McCoy cell line it has been established that many other cell lines are also suscep ⁇ tible to chlamydia (Croy, T.R. , C.C. Kuo, and S.P. Wang, 1975, "Comparative susceptibility of eleven mammalian cell lines to infection with trachoma organ ⁇ isms", J.Clin. Microbiol.
  • the cells are usually pre-treated or after-treated so as to prevent their division and to increase the cell-internal division of chlamydia.
  • the practical problems related to irradiation have resulted in the use of alternative methods in the . treatment of the cells.
  • E cobalt source for the purpose of irradiation.
  • all compounds that inhibit the metabolism of cells and all cytotoxic compounds may have some effects of health risk on the laboratory personnel.
  • the employment of different cell lines and treatments will establish that the best technique for the isolation of chlamydia has not been discovered as yet.
  • the method in accordance with the present invention is mainly characterized in that the sample is inoculated in the cells of a cultured cell line grown out of epithelial cells of an embryo of the mouse species Mus musculus castaneous.
  • An epithelial cell is the primary object of a chlamydial infection in man. Since it is difficult to produce non-transformed, pure epithelial cell cul- tures, experimental infection of epithelial cells has been difficult to produce.
  • Successful culture of a stable epithelial cell line isolated from the embryo of the mouse species Mus musculus castaneous, MMC-E (Rapp, U.R., J. Keski-Oja, and U.I. Heine, 1979, "Establishment and characterization of the epithelial mouse embryo cell line MMC-E", Cancer Res. 39:4111-4118) and character ⁇ ization of the cell line have permitted a study in vitro of various aspects of such diseases as usually produce al ⁇ terations in the epithelium.
  • the MMC-E cell line was originally isolated from an embryo of Mus musculus castaneous and was classified as epithelial on the basis of its morphology. In a MMC-E culture, dense joints and desmosomic struc ⁇ tures are seen when examined as highly enlarged. In imm ⁇ nofluorescence, little quantities of the fibronec- tine of the cell surface are seen and, moreover, out of the cultures, by means of virus transformation, REA
  • the cells also contain keratin filaments, which are a specific feature of the epithelial cells (Keski-Oja, J., Lehto, V.-P., and Virtanen I., 1981, "Keratin filaments of cultured mouse epithelial cells are rapidly affected by epidermal growth factor", J. Cell Biol. 90:531-541).
  • the MMC-E cells are not tumorigenic in "nude-mice", and therein large quantities of receptors of "epidermal growth factor” (EGF) appear.
  • the EGF may stimulate the cells to divide themselves, and produces morphological alterations resembling differen ⁇ tiation (Keski-Oja, J., I.U. Heine, U.R. Rapp, arid B. Wetzel, 1980, "Epidermal growth factor-induced alterations in proliferating mouse epithelial cells", Exp. Cell Res. 128:279-290.
  • the "murine sarcoma" growth factors produce a transformed phenotype in these cells (Keski-Oja, J. , J.E. DeLarco, U.R. Rapp, and G.J. Todaro, 1980, "Murine sarcoma growth factors affect the growth and morphology of cultured mouse epithelial cells", J. Cell Physiol. 104:41-46).
  • the untreated embryo epithelial cell line MMC-E of Mus musculus castaneous is equally susceptible to infection with Chlamydia trachomatis as the standard McCoy method in which irradiated cells are used, and it possesses remarkable advantages both in clinical routine diagnosis and in_ vitro when studying an experi ⁇ mental chlamydial infection of epithelial cells.
  • MMC-E cells are susceptible to infection with
  • Chlamydia trachomatis without any pre- or after-treat ⁇ ment are comparable with irradiated McCoy cells, which are usually used for the isolation.
  • MMC-E cells treated with cycloheximide permit routine dia ⁇ gnoses of chlamydia infections in ever more and more laboratories and are useful in studies in vitro of the mechanisms related to chlamydial infections of epi ⁇ thelial cells.
  • MMC-E cells for the isolation of chlamydia is useful for routine diagnoses of chlamydial infections, at least in such laboratories in which the pre-treatments of McCoy cells are too difficult to perform.
  • the use of MMC-E cells thereby permits the performance of chlamydia isolation tests in ever more and more laboratories.
  • the MMC-E cells were grown in plastic flasks treated for cell culture (Tissue culture plastic petri dish) in BHK-liquid to which 10 % of calf embryo serum and 50 ⁇ g/mg of gentamycin had been added.
  • the origi ⁇ nal cells were detached for passaging with trypsin-EDTA on a weekly basis in the ratio of 1:5.
  • About 3 x 10 ⁇ cells were grown in 1.0 ml of nutrient liquid in a plane-bottom plastic tube, which contained a round, 13 mm diameter sterilized covering glass to which the cultured cells adhered.
  • the strain used was ____ trachomatis serotype L2 (434Bu) , which had been originally obtained from an
  • the cells were incubated for two days at 37°C.
  • iodine colouring the nutrient liquid was removed from the tube and 1 ml of methanol was added, and the mix was allowed to stand for 10 minutes at the room temperature.
  • the methanol was removed and 1 ml of colouring liquid sold under the trade mark Lugol was added (manufacturer: Merck, Darmstadt) , and the mix was allowed to stand for 20 minutes at the room temperature.
  • the colouring liquid was removed and the covering glass was removed out of the tube.
  • the counting of the iodine-coloured inclu ⁇ sions was performed by means of the standard technique under microscope (Paavonen, J. , M. Kousa, P. Saikku, E. Vesterinen, E.
  • MMC-E cells In stead of untreated MMC-E cells, it is also possible to use, e.g., MMC-E cells treated with cyclo- heximide. The treatment then takes place in the same way as the treatment of McCoy cells.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicinal Chemistry (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Procédé d'isolation de chlamydia pour diagnostiquer une infection chlamydienne. L'échantillon clinique est inoculé dans les cellules d'une souche de cellule de culture cultivée à partir de cellules épithéliales d'un embryon de l'espèce de souris Mus musculus castaneous, et les inclusions sont détectées. Dans le procédé, les cellules non traitées d'un bouillon de culture de cellules confluantes peuvent être utilisées.
EP19830900038 1981-12-15 1982-12-15 Procede d'isolation de chlamydia Withdrawn EP0097196A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FI814023 1981-12-15
FI814023A FI63778C (fi) 1981-12-15 1981-12-15 Foerfarande foer isolering av klamydia

Publications (1)

Publication Number Publication Date
EP0097196A1 true EP0097196A1 (fr) 1984-01-04

Family

ID=8514957

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19830900038 Withdrawn EP0097196A1 (fr) 1981-12-15 1982-12-15 Procede d'isolation de chlamydia

Country Status (5)

Country Link
EP (1) EP0097196A1 (fr)
JP (1) JPS58502083A (fr)
FI (1) FI63778C (fr)
SU (1) SU1296011A3 (fr)
WO (1) WO1983002122A1 (fr)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4118469A (en) * 1976-04-27 1978-10-03 Research Corporation Antigen for trachoma lymphogranuloma venereum (LGV) and non-gonococcal urethritis (NGU)
EP0017460A1 (fr) * 1979-04-02 1980-10-15 Research Corporation Méthode d'examen par immunofluorescence et substance utilisée
US4427782A (en) * 1981-03-03 1984-01-24 Caldwell Harlan D Isolation of principal outer membrane protein and antigen of Chlamydia trachomatis

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO8302122A1 *

Also Published As

Publication number Publication date
FI63778C (fi) 1983-08-10
WO1983002122A1 (fr) 1983-06-23
JPS58502083A (ja) 1983-12-08
FI63778B (fi) 1983-04-29
SU1296011A3 (ru) 1987-03-07

Similar Documents

Publication Publication Date Title
de Madrid et al. A simple micro-culture method for the study of group B arboviruses
Mirelman et al. Entamoeba histolytica: effect of growth conditions and bacterial associates on isoenzyme patterns and virulence
Borchardt et al. A comparison of the sensitivity of the InPouch TV, Diamond's and Trichosel media for detection of Trichomonas vaginalis.
Young et al. Rapid carbohydrate utilization test for the identification of Neisseria gonorrhoeae.
Stuckey et al. Identification of Ureaplasma urealyticum (T-strain Mycoplasma) in patient with polyarthritis
Zawaneh et al. Factors influencing adherence of group B streptococci to human vaginal epithelial cells
Doane et al. Application of electron microscopy to the diagnosis of virus infections.
Harrison et al. Infection of untreated primary human amnion monolayers with Chlamydia trachomatis
Jalil et al. Infection of the epididymis by Ureaplasma urealyticum.
Clark et al. Identification of Mycoplasmataceae by the fluorescent antibody method
Mondal et al. Isolation, identification and characterization of Salmonella from duck
Smith Detection of Trichomonas vaginalis in vaginal specimens by direct immunofluorescence assay
EP0097196A1 (fr) Procede d'isolation de chlamydia
DK Human tissue culture studies of non-gonococcal urethritis.
RU2098486C1 (ru) Способ диагностики бактериемии
US2709670A (en) Diagnostic method using treponema pallidum
Ikechukwu et al. Role of enriched media in bacterial isolation from semen and effect of microbial infection on semen quality: A study on 100 infertile men
Morton et al. Virus culture studies in non-gonococcal urethritis
RU2723024C1 (ru) Способ дифференциальной диагностики хронического рецидивирующего цистита
Kobayashi et al. Cytologic detection of herpes simplex virus DNA in nipple discharge by in situ hybridization: report of two cases
Price THE OXIDASE REACTION IN THE LABORATORY DIAGNOSIS OF GONORRHOEA.
Al-Abdullah Empowering Women's Health: Investigating Bacterial Pathogens and Antibiotic Resistance for Personalized Vaginal Infection Care
RU2630060C1 (ru) Способ определения адгезии микроорганизмов на эпителиальных клетках слизистой оболочки полости рта и клеточной линии НЕр 2
Blenk et al. Activity of erythromycin against chlamydiae in vitro and in vivo, and its use in genital Chlamydia infections
CN106497866A (zh) 一种人正常阴道上皮细胞及其用途

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19830714

AK Designated contracting states

Designated state(s): AT BE CH DE FR GB LI LU NL SE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19860425

RIN1 Information on inventor provided before grant (corrected)

Inventor name: PARTANEN, PAUL

Inventor name: KESKI-OJA, JORMA

Inventor name: SUOVANIEMI, OSMO